Cytomedix lands FDA clearance for its plasma system

Fri, 11/09/2012 - 10:45am
Mass Device

The FDA clears Cytomedix's Angel concentrated platelet rich plasma system, an advanced autologous whole blood and bone marrow separation technology, with which the company hopes to expand its orthopedic footprint.

Cytomedix logo

Cytomedix (OTC:CMXI) received FDA clearance for its Angel concentrated platelet rich plasma system, a whole blood separation system designed to produce consistently high platelet yields.

Angel PRP, the only PRP system with adjustable settings to customize plasma formulations, can prepare plasma from whole blood samples either at the patient's point-of-care or in a clinical setting, according to the company's website.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.